Holen Sie sich die Stockscreener-App
6.98
0.78%
-0.05
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Lost Money on Replimune Group, Inc.(REPL)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - MarketScreener
Important Notice to Long-Term Shareholders of Centene - GlobeNewswire
Traders Buy Large Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World
Unpacking the Sharp Drop in Replimune Group (REPL.O): A Technical and Order-Flow Deep Dive - AInvest
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman - PR Newswire
The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
Why Is Replimune Stock (NASDAQ:REPL) Exploding? - TipRanks
Replimune's Stock Volatility: Navigating Biotech Uncertainty and Immuno-Oncology's Long-Term Promise - AInvest
How to escape a deep drawdown in Replimune Group Inc.Free Beginner Friendly Stock Selection Guide - Newser
Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval - Stocktwits
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Replimune stock rises as Cantor Fitzgerald upgrades (REPL) - Seeking Alpha
Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector - Stocktwits
Replimune Group: Unexpected Surge Analysis - StocksToTrade
Important Notice to Short and Long-Term Shareholders of - GlobeNewswire
REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc. - Morningstar
Order flow analysis tools used on Replimune Group Inc.Chart-Based Entry Confirmation for Beginners - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - The Malaysian Reserve
Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - GlobeNewswire Inc.
Replimune Faces Investor Lawsuit Over IGNYTE Trial - TipRanks
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on September 22, 2025 - ACCESS Newswire
Replimune Group (REPL.O) Sees Sharp Intraday Surge — But Why? - AInvest
Replimune Faces Market Turbulence: FDA Rejection Leads to Legal Trouble - StocksToTrade
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Morningstar
Combining machine learning predictions for Replimune Group Inc.AI Entry Timing Prediction for Swing Traders - Newser
Market reaction to Replimune Group Inc.’s recent newsFree Stock Market Watch With Alerts - Newser
How to track smart money flows in Replimune Group Inc.Trend Reversal Probability Forecast Update - Newser
Investors in Replimune Group, Inc. (REPL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Replimune’s SWOT analysis: biotech stock faces FDA setback, industry remains positive - Investing.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after - GlobeNewswire
REPL LAWSUIT NOTICE: Replimune Group, Inc. Investors are Notified of the Pending Securities Fraud Class ActionContact BFA Law before the September 22 Deadline - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
Ongoing Investigation: Replimune Group, Inc. (REPL) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Replimune Group, Inc. (REPL) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Important Notice to Long-Term Shareholders of Alto - GlobeNewswire
REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc. - GlobeNewswire
Using portfolio simulators with Replimune Group Inc. includedFree Buy Low Sell High Stock Watch - Newser
Order flow analysis tools used on Replimune Group Inc. Buy/Sell Zone Confirmation Technical Analysis - Newser
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Securities Litigation in Biotech: Navigating the Replimune Crisis and Its Broader Implications - AInvest
Regulatory Setbacks and Legal Risks: Replimune Group's Turbulent Path in the Biotech Sector - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - WV News
Leerink Partnrs Expects Lower Earnings for Replimune Group - Defense World
REPL CLASS ACTION ALERT: FDA Response Letter Leads to - GlobeNewswire
Replimune Group (NASDAQ:REPL) Cut to “Underperform” at BMO Capital Markets - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Equal Weight” at Barclays - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Neutral” at HC Wainwright - Defense World
REPLIMUNE GROUP, INC. (NASDAQ: REPL) INVESTOR ALERT Investors With Large Losses in Replimune Group, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - ACCESS Newswire
[REPL] ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. Investors - TradingView
Potential Securities Fraud: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Is Replimune Group Inc. a good long term investmentTremendous wealth creation - PrintWeekIndia
ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Ongoing Replimune Group, Inc. (REPL) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending - GlobeNewswire
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline - FinancialContent
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):